Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytosorbents Corporation - Common Stock (NQ:CTSO)

0.8500 -0.0355 (-4.01%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cytosorbents Corporation - Common Stock

< Previous 1 2 3 4 Next >
Deep Dive Into CytoSorbents Stock: Analyst Perspectives (5 Ratings)
 
Via Benzinga
Wednesday's pre-market session: top gainers and losers
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
CytoSorbents's Earnings: A Preview
 
Via Benzinga
Insights into CytoSorbents's Upcoming Earnings
 
Via Benzinga
Demystifying CytoSorbents: Insights From 5 Analyst Reviews
 
Via Benzinga
CytoSorbents Corp (NASDAQ:CTSO) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower Loss
CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb. 
Via Chartmill
A Glimpse Into The Expert Outlook On CytoSorbents Through 5 Analysts
 
Via Benzinga
Top movers in Wednesday's session
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts
 
Via Benzinga
Analyst Scoreboard: 5 Ratings For CytoSorbents
 
Via Benzinga
These stocks are moving in today's session
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Gapping stocks in Wednesday's session
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Deep Dive Into CytoSorbents Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Demystifying CytoSorbents: Insights From 4 Analyst Reviews
 
Via Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
 
Via Benzinga
Recap: CytoSorbents Q4 Earnings
 
Via Benzinga
Earnings Scheduled For May 14, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts
 
Via Benzinga
Earnings Scheduled For March 31, 2025
 
Via Benzinga
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth
CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device. 
Via Benzinga
Topics Supply Chain
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why CytoSorbents (CTSO) Stock Is Trading Higher
CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group. 
Via Benzinga
CTSO Stock Earnings: CytoSorbents Meets EPS, Beats Revenue for Q1 2024
CTSO stock results show that CytoSorbents met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.